BTIG Rates Innoviva (INVA) buy, $42 Price Target
BTIG maintains its buy rating for INVA, targeting $42, as shares trade near $22.67, a 77.66% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Innoviva, Inc. ($INVA) "buy" with a $42 price target on June 22, 2026.
Since the rating, $INVA is up 2.1% after 1 week, down 5.5% after 1 month and down 8.3% to date (from the $22.67 close on Jun 22, 2026).
INVA
Innoviva, Inc.
Key Points
- BTIG reiterated its buy rating on INVA with a price target of $42 on June 22, 2026.
- BTIG's $42 price target implies 77.66% upside from Innoviva, Inc.'s ($INVA) current $23.64 share price.
- INVA shares traded around $22.67 on Tuesday, reflecting ongoing market interest.
- Recent insider activity includes sales by top executives on May 20, 2026.
Get $INVA trade alerts by text
We text you when insiders, Congress or big funds trade $INVA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Innoviva, Inc. alert may contain errors. Disclosures
BTIG maintained its buy rating on INVA, setting a price target of $42. This reiteration was announced on June 22, 2026, reflecting continued confidence in the company's potential. INVA shares were trading around $22.67 on Tuesday, suggesting a positive outlook from the analyst community.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in INVA
BlackRock, Inc. grew its holdings in INVA by 631,070 shares, ending with 11,307,845 shares worth about $263.5 million. Dimensional Fund Advisors LP added 76,026 shares, bringing its total to 4,436,427 shares valued at approximately $103.4 million. Vanguard Portfolio Management LLC opened a new position with 4,224,951 shares valued at nearly $98.4 million. Meanwhile, Renaissance Technologies LLC reduced its stake by 154,540 shares, leaving it with 4,055,632 shares worth about $94.5 million. State Street Corp increased its holdings by 263,557 shares to 3,060,377 shares, valued at roughly $71.3 million.
Innoviva, Inc. Stock Up 11.8%
Shares of INVA traded near $22.67 on Tuesday. While specific market cap and P/E ratio details aren't available, the stock's recent activity and analyst rating suggest ongoing interest.
$INVA price target
Innoviva, Inc. daily closes and this analyst's $42 target. Not advice.
Insider Buying and Selling at Innoviva, Inc.
On May 20, 2026, several top executives at INVA, including CFO Stephen Basso and CEO Pavel Raifeld, sold shares at an average price of $22.24. Basso sold 559 shares, while Raifeld sold 1,130 shares. Chief Accounting Officer Marianne Zhen also sold 1,127 shares. Earlier, on May 15, 2026, Raifeld and Basso each bought 1,123 shares, and Josephine Linden acquired 9,166 shares on May 18, 2026.
Analysts Set New Price Targets
On June 22, 2026, BTIG maintained its buy rating for INVA with a $42 price target. Earlier, on June 1, 2026, HC Wainwright & Co. reiterated a buy rating with a $46 target. These ratings highlight strong analyst support for INVA.
About INVA
INVA operates in the healthcare sector, focusing on innovative solutions to improve patient outcomes. The company is committed to advancing medical technology and is based in the United States. With a team dedicated to research and development, INVA aims to lead in its industry.
Bottom Line
BTIG's reiterated buy rating and $42 price target for INVA underscore the analyst's confidence in the company's prospects. With shares trading around $22.67, investors are keeping a close watch on INVA's performance. The 13F filings and insider transactions provide a backward-looking view, offering insights into institutional sentiment and executive actions.
Related Filing Alerts
Source: BTIG's rating change on $INVA (Jun 22, 2026). Written by software, not financial advice. How we make alerts